Last reviewed · How we verify
NCT03739281
PET/MR Imaging in Lung Cancer
NA trial testing PET/MR in Lung Cancer in 35 participants. Terminated before completion.
31 December 2022
Quick facts
| Lead sponsor | University Hospital of North Norway |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 35 |
| Start date | 12 December 2018 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- PET/MR
- PET/CT
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
University Hospital of North Norway
Who can join
Eligibility, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this project is to investigate if PET/MR imaging improves the accuracy in visualization and characterization of lung cancer disease, compared to PET/CT.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03739281
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PET/MR
Trials testing the same drug.
- NCT06092125 — Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease · recruiting
- NCT05006326 — Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma · NA · unknown
- NCT04271436 — Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT · Phase 2 · withdrawn
- NCT04552847 — Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors · Phase 2, PHASE3 · completed
- NCT04271254 — PET/MR Characterization of Renal Cell Carcinomas · NA · terminated
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other University Hospital of North Norway trials
Trials by the same sponsor.
- NCT07343895 — Population-based Atrial Fibrillation Screening in Individuals With NT-proBNP Above Median in the Tromsø Study · NA · recruiting
- NCT07149246 — The Effect of a 6-month Dietitian-tailored Nutrition Intervention to Patients With Critical Illness (DETAIL) · NA · recruiting
- NCT07092904 — Myocardial Infarction Safe Emergency Medicine Accompanying Study: Providing Reperfusion Therapy Within the Recommended T · not yet recruiting
- NCT07530588 — Decentralized Imaging by REmote Computer Tomography for Cerebral Infarct Thrombolysis · NA · recruiting
- NCT06881758 — High Intensity Training for Patients with Anxiety · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03739281 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital of North Norway
- Last refreshed: 17 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03739281.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing